What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?

被引:41
作者
Descazeaud, A
Rubin, MA
Allory, Y
Burchardt, M
Salomon, L
Chopin, D
Abbou, C
de la Taille, A
机构
[1] Hop Henri Mondor, INSERN, EMI03 3, Dept Urol & Pathol, F-94000 Creteil, France
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Univ Dusseldorf, Dept Pathol, Dusseldorf, Germany
关键词
prostate cancer; needle biopsy; pathology report; gleason score; survey;
D O I
10.1016/j.eururo.2005.07.011
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: This survey-based study examines what information urologists are extracting from prostate needle biopsy reports, and what they need for clinical management of prostate cancer (PC) patients. Methods: A questionnaire was used to investigate several topics related to PC biopsy reporting. Two different clinical situations were separately explored, depending on whether the urologist intended a curative or a palliative therapy. Results: 110 of the 300 (37%) urologists responded to the questionnaire and returned anonymous responses. The mean age of respondents was 47.5 years old (range 27-66). On average, they performed 31 (range 0-182) radical prostatectomies per year. Before proposing a curative therapy, several biopsy parameters were requested by the majority of respondents, including number of positive biopsies (104/110 or 95%), Gleason score (103/110 or 94%), highest Gleason grade (94/110 or 85%), localization of positive biopsies (80/110 or 73%), length of tumor on biopsy (58/110 or 53%), presence of extraprostatic extension (66/110 or 60%). In a palliative situation, only three parameters were requested by the majority of respondents: Gleason score (101/110 or 92%), highest Gleason grade (67/110 or 61%) and number of positive biopsies (59/110 or 54%). In prostate needle biopsies harboring cancer on multiple cores from separately designated locations, 77% (68/88) of respondents used the highest Gleason score, regardless of the overall percentage involvement, to determine their treatment plan. PIN (Prostatic Intraepithelial Neoplasia) on biopsy without PC was considered sufficient to re-biopsy by 77% (85/110) of respondents. Thirty six percent (40/110) of the respondents considered ASAP (Atypical Small Acinar Proliferation) to be equivalent to PIN. There was no significant association between the demographic data and the type of information requested on the biopsy report. Conclusions: In this sample of 110 French and Belgian urologists there was high variability in the way clinicians use prostate needle biopsy pathology report. Results of this survey should improve communication between urologists and pathologists and should help evaluate what data should be included in routine pathology reports. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:911 / 915
页数:5
相关论文
共 18 条
[1]  
Amin MB, 1996, AM J CLIN PATHOL, V105, P667
[2]   Handling and pathology reporting of prostate biopsies [J].
Boccon-Gibod, L ;
van der Kwast, TH ;
Montironi, R ;
Boccon-Gibod, L ;
Bono, A .
EUROPEAN UROLOGY, 2004, 46 (02) :177-181
[3]   Pathologic features the urologist should expect on a prostate biopsy [J].
Che, MX ;
Sakr, W ;
Grignon, D .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (02) :153-161
[4]   Atypical small acinar proliferation of the prostate gland [J].
Epstein, JI .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (11) :1430-1430
[5]   Sampling, submission, and report format for multiple prostate biopsies: A 1999 survey [J].
Iczkowski, KA ;
Bostwick, DG .
UROLOGY, 2000, 55 (04) :568-571
[6]   Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies - Clinical significance in 33 cases [J].
Iczkowski, KA ;
MacLennan, GT ;
Bostwick, DG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1997, 21 (12) :1489-1495
[7]   ASAP [J].
Wightman, HR .
HUMAN PATHOLOGY, 1999, 30 (12) :1403-1403
[8]   Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer [J].
Kattan, MW ;
Potters, L ;
Blasko, JC ;
Beyer, DC ;
Fearn, P ;
Cavanagh, W ;
Leibel, S ;
Scardino, PT .
UROLOGY, 2001, 58 (03) :393-399
[9]   A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer [J].
Kattan, MW ;
Eastham, JA ;
Stapleton, AMF ;
Wheeler, TM ;
Scardino, PT .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (10) :766-771
[10]   Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer [J].
Kattan, MW ;
Zelefsky, MJ ;
Kupelian, PA ;
Scardino, PT ;
Fuks, Z ;
Leibel, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) :3352-3359